How Do You Know When to Higher Dose of Levothyroxine

Adv Ther. 2019; 36(Suppl two): 30–46.

Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime

Leonidas H. Duntas

^aneUnit of Endocrinology, Diabetes, and Metabolism, Thyroid Department, Evgenidion Hospital, Athens, Greece

Jacqueline Jonklaas

²Partition of Endocrinology, Georgetown Academy, Washington, DC USA

Abstract

Levothyroxine is the standard therapy for patients with hypothyroidism, a condition that affects up to 5% of people worldwide. While levothyroxine therapy has substantially improved the lives of millions of hypothyroid patients since its introduction in 1949, the complexity of maintaining biochemical and clinical euthyroidism in patients undergoing treatment with levothyroxine cannot be underestimated. Initial dosing of levothyroxine can vary greatly and may be based on the amount of residual thyroid part retained past the patient, the body weight or lean torso mass of the patient, and thyroid-stimulating hormone levels. As levothyroxine is usually administered over a patient'south lifetime, physiological changes throughout life will affect the dose of levothyroxine required to maintain euthyroidism. Furthermore, dose adjustments may need to be made in patients with concomitant medical conditions, in patients taking certain medications, as well as in elderly patients. Patients who have undergone whatsoever weight or hormonal changes may require dose adjustments, and the majority of pregnant women require increased doses of levothyroxine. Optimal treatment of hypothyroidism requires a partnership between patient and md. The dr. is tasked with vigilant appraisal of the patient's status based on a thorough clinical and laboratory assessment and appropriate aligning of their levothyroxine therapy. The patient in turn is tasked with medication adherence and reporting of symptomatology and any changes in their medical situation. The goal is consistent maintenance of euthyroidism, without the patient experiencing the adverse events and negative health consequences of under- or overtreatment.

Funding Merck.

Plain Language Summary Manifestly language summary bachelor for this article.

Keywords: Dose aligning, Endocrinology, Hypothyroidism, Levothyroxine, Lifespan, Medical conditions, Medications

Plain Linguistic communication Summary

Hypothyroidism, a reduction in thyroid hormone levels, is one of the nigh common diseases worldwide. The medication most used to treat hypothyroidism is levothyroxine, a compound that acts as a replacement for a person'southward thyroid hormone. People with hypothyroidism will often need to take levothyroxine for a long time, typically for the rest of their life, and so information technology is of import that their treatment is monitored closely and the dose is adapted for the best effect as needed. As a person progresses through life, their dose may demand to be adjusted because other diseases or medications can affect the dose needed for effective handling. Pregnancy or weight gain can too affect the dose of levothyroxine needed by the patient, then patients and physicians demand to work in partnership to ensure that the handling is working likewise as it can. The goal of this partnership is to maintain normal thyroid hormone levels without the patient experiencing whatever side effects or negative health consequences of taking too much or also piffling levothyroxine.

Introduction

Thyroxine was isolated on Christmas Day 1914 by Kendall. Its chemical structure was determined in 1926 by Harington, and it was synthesised in 1927 past Harington and Barger [1, 2]. The acidity of the thyroxine molecule, which acquired diminished assimilation resulting in low bioavailability, was an unresolved problem for more than 20 years post-obit its discovery [3]. In 1949, a commercial product containing synthesised sodium thyroxine was launched in the USA and some years after in Europe, signalling a new era in the handling of hypothyroidism, which had advanced from partially purified extracts of bovine thyroid gland and desiccated thyroid extracts from sheep and pigs to fully synthesised thyroxine [4, 5]. The industry of sodium thyroxine (levothyroxine) thus resulted in a major pharmacological achievement in endocrinology, giving a more stable and constructive thyroid hormone compound that, over the last few decades, has considerably improved the lives of millions of patients with various forms of hypothyroidism.

The objective of this review is to provide an overview of (1) when administration of levothyroxine is necessary, (2) initial dosing and subsequent adjustment of levothyroxine, (3) the importance of avoiding under- and over-treatment with levothyroxine, (4) the need for levothyroxine dose adjustment through diverse phases of life, (5) medical conditions and medications necessitating levothyroxine dose adjustments, too as (half dozen) controversies near treatment with products other than levothyroxine. Diligent monitoring of patients taking levothyroxine and regular dose adjustment to reach optimised treatment and avoidance of adverse events are particularly emphasised.

Methods

A search of the literature was conducted using the PubMed and Key (Cochrane) databases. Keywords relating to levothyroxine, hypothyroidism, treatment, levothyroxine dose adjustments, levothyroxine and concomitant conditions, levothyroxine and concomitant medications, and combined treatment with levothyroxine and liothyronine versus levothyroxine were searched. Only reviews and articles providing clinical data, particularly the nearly recent, were considered. Potential articles of interest were identified by title and abstract, and citation lists of articles of involvement were used to identify additional literature. This commodity is based on previously conducted studies and does non contain any studies with animals performed past any of the authors. Some of the studies cited include analyses, or studies with homo participants, performed by the authors and completed prior to the initiation of this manuscript.

When Levothyroxine Administration Is a Necessity

Thyroxine is secreted by the thyrocytes and is the main thyroid hormone in the apportionment. Thyroxine is actively transported to the various organs where it is converted to triiodothyronine by the activity of the deiodinases [6]. Triiodothyronine, the active grade of thyroid hormone, is secreted in small amounts by the thyroid but is mainly generated via extrathyroidal conversion of the prohormone thyroxine. Hypothyroidism is a common endocrine disease that requires timely and lifelong treatment since, if left untreated, information technology can contribute to hypertension, dyslipidaemia, and centre failure and induce reversible dementia and infertility, as well equally neurosensory, musculoskeletal, and gastrointestinal symptoms [7]. There is currently no other treatment for hypothyroidism, other than providing thyroid hormone replacement. Due to its long half-life of nearly 7 days, in patients in the clinically euthyroid state, levothyroxine is the preferred kickoff-line handling for primary hypothyroidism and has been the most commonly prescribed treatment since the 1980s [8].

Initial Dosing and Dose Aligning of Levothyroxine During Therapy

Initial Dosing

The levothyroxine dose initially required by a patient depends primarily on three factors: the amount of residual thyroid function retained by the patient, the body weight or lean body mass of the patient, and the target thyrotropin or thyroid-stimulating hormone (TSH) level to be accomplished during therapy [8]. Boosted factors such every bit patient age, patient sexual activity, and menopausal status may have an influence that is generally of lesser magnitude. Other physiological factors such as pregnancy and gastrointestinal functioning may be important factors in specific patients or at specific times [8].

When commencing levothyroxine therapy, initial dose requirements can vary greatly from small doses such as 25–fifty μg in an individual with balmy or subclinical disease, where the therapy may exist supplementing endogenous function, to larger doses of 88–175 μg in cases of patients with negligible endogenous thyroid function. In keeping with this concept, the initial dose of levothyroxine in patients presenting to a clinic with primary hypothyroidism tin can be predicted by the patient's TSH value prior to initiation of treatment [9]. In the case of surgically athyreotic patients, the dose of levothyroxine required may be slightly higher than in those with autoimmune thyroid disease [eight], presumably reflecting some retained thyroid hormone production in those with autoimmune thyroid disease. An example of the dose requirement in those with Hashimoto'southward thyroiditis without residual function and post-surgical hypothyroidism is approximately 1.half dozen μg/kg [eight]. The dose of levothyroxine required by a patient following thyroidectomy tin exist predicted past either trunk weight or trunk mass alphabetize (BMI) [10–12]. Body weight, BMI, ideal trunk weight, and lean body mass can all predict the initial dose requirement, with the latter 3 parameters providing the more than accurate estimates [10, 13]. Various formulae have been proposed to calculate dose requirement. These range from simple formulae based only on body weight or BMI to more than circuitous formulae that also incorporate other factors such equally patient sexual practice [10, 14]. Generally, both a TSH-based estimate and a body weight-based estimate yield similar initial estimates of dose requirement (Fig.i). With respect to age, for patients who are elderly, have concomitant cardiac disease, or may have had long-standing untreated hypothyroidism, it is wise to initiate levothyroxine therapy with smaller doses such as 25–l μg levothyroxine and incrementally increase the dose to full replacement to avoid precipitating cardiac ischaemia [8].

Instance of torso weight- and thyroid-stimulating hormone-based levothyroxine initial dose estimates. BMI body mass index, FT4 gratuitous thyroxine, LT4 levothyroxine, TSH thyroid-stimulating hormone

Dose Aligning

Regardless of the method used to guess the initial levothyroxine dose requirement, dose adjustment is ofttimes required. This may be due to multiple factors including limitations in the dose requirement predictions, inter-patient variation, levothyroxine absorption, or furnishings of concomitant medical conditions or medications [8]. Given the one-half-life of levothyroxine (approximately 1 week), reassessment of thyroid condition by serum TSH levels, and free thyroxine levels if desired, is indicated after 6 weeks of therapy when the pharmacokinetic steady state is reached. If the TSH is non at the desired goal, the levothyroxine dose can be adjusted up or down. TSH values that are slightly out of range may be corrected by a single dose increment or decrement, such as increasing from 100 to 112 μg or decreasing from 175 to 150 μg. TSH values that are considerably out of range may require larger pct changes. Levothyroxine absorption is maximised, at about 75% of the administered dose, when it is ingested upon an empty stomach [8]. Therefore, if levothyroxine is taken at other times of the 24-hour interval for convenience, the dose requirement may be greater and potentially more variable [fifteen]. In one case the desired TSH value has been achieved, it could potentially be re-confirmed by laboratory testing in iii–6 months, and and so checked on an annual ground thereafter. A stable TSH while receiving levothyroxine therapy was inversely associated with the magnitude of the levothyroxine dose in one study, perhaps suggesting that residuum thyroid office provided some buffer against TSH variations in those who required smaller levothyroxine doses [16].

Simple regimens that involve the same dose taken daily are ideal with respect to ease of adherence, although sometimes regimens that involve alternate doses or use of half tablets are needed to accomplish the desired TSH value. A study comparing TSH values achieved with use of whole levothyroxine tablets versus split tablets showed comparable TSH values [17], but nevertheless any unnecessary complications to a regimen that patients will be post-obit for a lifetime need to exist minimised. There do seem to exist a diverseness of costs, such as utilisation of health care resources, and comorbidities, such as depression and dyslipidaemia, associated with non-adherence to levothyroxine therapy, as demonstrated in a study funded by levothyroxine manufacturers [18]. Not-adherence to levothyroxine is generally associated with an elevated TSH. However, if missed doses are non reported by the patient, levothyroxine dose increases can lead to a low TSH if therapy is later adhered to. If issues with non-adherence and an elevated TSH are not corrected by educational activity or treatment of contributing weather such equally low or psychiatric disorders, possible solutions to improve adherence include observed weekly oral levothyroxine therapy (Fig.two) [19, 20] or weekly or twice weekly parenteral administration (such every bit intravenous [21], subcutaneous [22], or intramuscular administration of levothyroxine [23]).

Example of how to address non-adherence to levothyroxine associated with elevated thyroid-stimulating hormone levels. 25 (OH) vitamin D 25-hydroxy vitamin D, FT4 free thyroxine, LT4 levothyroxine, TSH thyroid-stimulating hormone

Avoidance of Over- and Nether-Dosing with Levothyroxine

Generally, hypothyroidism may be effectively treated via a constant daily dose of levothyroxine, and, for the majority of confirmed aetiologies, this needs to be lifelong. However, in this setting, there announced to be many cases of both levothyroxine over- and under-dosing and it may be that frequent adjustments of a dose are necessary. These adjustments need to be handled with caution and have into account the many contributing factors, as multiple levothyroxine dose adjustments evidently result in a greater burden on healthcare resources [24]. This means that information technology is necessary for clinicians to decide which patients are truly in need of dose adjustment. Even more than importantly, accumulating show suggests that many patients, for whom the indication for levothyroxine initiation is non fairly established and the diagnosis is not well documented, are remaining on levothyroxine therapy for longer than necessary. A prospective clinical cohort follow-up written report illustrated this by showing that, among 291 patients (84% females) on levothyroxine replacement therapy without a solid diagnosis of hypothyroidism and in whom the handling was paused, 114 adult hypothyroidism, while 177 participants remained euthyroid. The latter results clearly betoken to a meaning overuse of levothyroxine therapy [25].

Overtreatment should particularly be avoided in the elderly. A study seeking to determine whether levothyroxine pharmacokinetics are affected by age and weight did not place any influence of age on the levothyroxine dose requirement, though it was adamant that weight may mediate age-related changes in levothyroxine pharmacokinetics [26]. In add-on, transient changes (east.yard., illness), inter- and intra-individual differences in thyroid parameters, or indigenous variations may modify the handling target, thus rendering appropriate a tailored assessment of thyroid function. Apply of thyroid excerpt, rather than levothyroxine, may be associated with overtreatment. In a study of 174 reports of adverse events occurring in patients taking thyroid hormone excerpt, 91 of these reports were accompanied by changes in TSH values and, of these, 62 patients (68%) had adult new symptoms associated with TSH changes, with most (65%) having symptoms consistent with thyrotoxicosis [27].

In a recent case report the authors draw two female person patients with Takotsubo cardiomyopathy associated with levothyroxine over-replacement, clearly underlining the necessity to arrange the dose of levothyroxine, peculiarly in patients with cardiovascular risks, so as to avert the deleterious effects of iatrogenic hyperthyroidism [28]. Some other point to exist considered in overzealously treated patients is the high risk of accelerated bone loss, predominantly in postmenopausal women, likewise every bit the risk of osteoporosis and vertebral fractures [29]. Concerning under-dosage, while overtreatment was not associated with impairment of health-related quality of life (HRQoL), patients who are undertreated had worse HRQoL than overtreated patients, particularly regarding physical and emotional aspects, independently of the degree of hypothyroidism [30]. Given that hypothyroidism undertreatment is associated with poor patient HRQoL, it is clear that levothyroxine therapy must be sufficient to maintain serum TSH within the reference range. Age-dependent interpretation of TSH values (extending from neonates to the very onetime), with appropriate consideration of circadian fluctuations, body weight, gastrointestinal diseases and malabsorption, comorbidity, and perchance pituitary insufficiency or thyroid hormone resistance, is thus crucial for optimal levothyroxine dosage.

Another gene that can be associated with under- or overtreatment with levothyroxine is switching between unlike preparations. Despite the availability of stable compounds of levothyroxine, over the past few decades, problems have repeatedly emerged concerning authorization, which, according to specifications issued by the US Food and Drug Administration in 2007, should non exceed 10% difference from the stated dose [31]. Furthermore, bioequivalence testing allows the 90% confidence interval of the difference in the areas under the curve and difference of maximum concentrations of serum T4 derived during pharmacokinetic testing to fall within 80–125% of that of a reference product [eight] or the more than stringent criteria of 90–111%. It is well known that dose differences falling inside this range event in clinically relevant dissimilarities in safety and effectiveness. In addition, any method of analysing bioequivalence data that does not accept into account endogenous thyroxine concentrations volition confound accurate quantitation and interpretation of levothyroxine bioavailability [32]. Hence, even products that meet the criteria for bioequivalence could well expose patients to the development of iatrogenic hyperthyroidism or hypothyroidism. While levothyroxine has a narrow therapeutic index [33], divers as having a narrow window between constructive doses and those at which they produce agin events, as well as a potential variance in the therapeutic efficacy among various levothyroxine preparations, there is at nowadays no viable alternative to this treatment.

In summary, it is necessary in all cases to periodically verify the need for dose aligning and/or continuation of handling. If in that location is a suspicion for levothyroxine handling having been prescribed unnecessarily, this tin can be investigated via a test period incorporating six- to viii-week therapy discontinuation, followed by TSH testing.

Factors Potentially Contributing to the Demand for Levothyroxine Dose Adjustments Throughout a Patient'southward Life Span

There are many factors encountered by patients across their life span that may be associated with an altered levothyroxine requirement. Newborns, children, and adolescents typically require higher levothyroxine doses than adults [8]. Examples of factors affecting the levothyroxine dose requirements of adults include pregnancy, weight changes, hormonal changes, and ageing.

Pregnancy

The dramatic increment in levothyroxine dose requirements associated with pregnancy, and the subsequent decrease in requirement post-partum are possibly the all-time documented alterations in levothyroxine requirement [34]. The reason for the increased requirement is the need for an increased full body thyroxine pool associated with increased thyroxine-binding globulin concentrations and increased plasma volume. Increased levothyroxine doses are required in approximately 50–85% of pregnant women, and the need for an increase occurs early in the get-go trimester. Requirements tend to stabilise as the patient progresses into the 2nd and third trimester, with few changes generally being required in the third trimester. The percentage increase in levothyroxine dose needed can be as high as xxx–l% and is highest when the crusade of the hypothyroidism is a thyroidectomy or ablation of the thyroid gland [35]. Achieving a serum TSH < 1.two mIU/l preconception seems to reduce the percentage of patients requiring a dose increase [36]. Studies show that serum TSH can be maintained at goal during pregnancy by either increasing the levothyroxine dose by 29% by increasing from seven to 9 tablets of levothyroxine weekly when conception is confirmed [37] or ongoing titration based on serum TSH [38]. The latter method had the advantage of resulting in fewer patients having a suppressed TSH during pregnancy [38]. Women undergoing in vitro fertilisation have similar needs for increased levothyroxine dosages, with 83% of women requiring an increase and the average increment being 33% [39].

Weight Changes and Hormonal Changes

As mentioned in a higher place, levothyroxine dose requirements are affected by body weight, platonic trunk weight, and lean torso mass, with dose requirements increasing every bit these parameters increment [eight, 13, xl]. However, if actual body weight is used to calculate the levothyroxine requirement in obese individuals, the dose may be overestimated, with ideal body weight beingness a ameliorate predictor [xl]. Moreover, the studies regarding levothyroxine requirement in obese individuals often yield differing results of either increased or decreased requirements, possibly because of competing effects of the increased body weight and the dumb absorption and altered levothyroxine kinetics that may be seen with obesity [41]. Dissimilar results take also been reported regarding the altered levothyroxine requirement associated with the weight loss seen afterward bariatric surgery. About studies show that such weight loss is associated with a reduced levothyroxine requirement [42], possibly due to both the reduced weight and improved absorption. However, bariatric procedures involving jejunoileal bypass may exist associated with an increased levothyroxine requirement because of reduced, equally opposed to improved, levothyroxine absorption [43]. In cases where levothyroxine assimilation is impaired after bariatric surgery, use of liquid levothyroxine may improve absorption [44].

With respect to hormonal changes, premenopausal women may require higher levothyroxine doses than postmenopausal women [xl, 45, 46]. Conversely, oestrogen therapy is associated with a need for higher doses of levothyroxine to maintain the same serum TSH [47].

Ageing

Several studies have shown that the levothyroxine dose requirement is decreased in older individuals [8, 48, 49]. However, a recent study suggests that this decreased requirement may be mediated past the changes in weight that may accompany ageing [26]. Other important considerations regarding levothyroxine doses in older individuals include bearing age-adjusted TSH reference ranges in heed [50] and avoiding over-replacement that might potentially exacerbate other medical weather condition [8]. Both of these considerations would lead to targeting of higher TSH values in older individuals (Fig.3).

Example of application of age-adjusted thyroid-stimulating hormone reference ranges to patient treatment. LT4 levothyroxine, TSH thyroid-stimulating hormone

Levothyroxine Dose Adjustments Associated with Concomitant Medical Conditions and Medications

Levothyroxine is best absorbed when the stomach environment is acidic and is captivated mainly in the jejunum and ileum [51]. Information technology is primarily metabolised by de-iodination, but also is metabolised by conjugation, decarboxylation, and deamination. Based on this route into and out of the body, there are many medical conditions and medications that can impact these steps and modify the levothyroxine dose requirement. Two studies illustrate the combined affect of medical conditions and medications [52, 53]. A report of a pharmaceutical visitor-sponsored database identified gastrointestinal weather and medications such as fe, calcium, and acid-lowering therapies every bit being associated with difficulty decision-making hypothyroid symptoms and frequent changes in levothyroxine doses [52]. Gastrointestinal conditions and interfering medications were likewise identified as being associated with the finding of patients requiring higher than predicted doses of levothyroxine in an audit of patients being treated past physicians in the national health organization in Scotland [53].

Medical Conditions

Generally speaking, although other chronic medical conditions such every bit cardiac disease, hepatic disease, osteoporosis, or diabetes do non directly impact levothyroxine dose requirements, some individuals with these conditions may exist elderly or delicate and thus extra caution may need to be exercised to avert nether- or over-dosing. One specific medical status in which levothyroxine doses that lower serum TSH may exist intentionally employed is differentiated thyroid cancer [54]. If TSH suppression is the goal in patients with intermediate- or high-take chances thyroid cancer, higher doses upwardly to ii.2 μg/kg body weight may be needed [8]. However, TSH suppression is not necessary in low-run a risk patients or in patients who no longer take a substantial take chances of thyroid cancer recurrence (Fig.4). Patients with hypothyroidism who are hospitalised with critical affliction may require higher doses of levothyroxine while hospitalised [55], possibly because of such factors equally use of proton pump inhibitors or decreased absorption associated with enteral feeding. Decreased absorption acquired past enteral feeding may be circumvented by temporarily holding tube feeds prior to levothyroxine administration or using liquid preparations of levothyroxine [56]. In that location may too be failure to prescribe levothyroxine appropriately in the hospital setting [57].

Example of balancing risks and benefits in order to choose a target thyroid-stimulating hormone value for a patient. LT4 levothyroxine, TSH thyroid-stimulating hormone

A variety of gastrointestinal conditions may be associated with decreased levothyroxine absorption and college serum TSH levels when the condition is untreated compared with when the status is treated [51]. These conditions include gastritis, coeliac affliction, and lactose intolerance. Helicobacter pylori-associated gastritis is associated with increased levothyroxine requirement, with the increased requirement resolving with treatment of the gastritis [58, 59]. Similarly, untreated coeliac disease is associated with a high levothyroxine requirement that is remediated past dietary handling of the coeliac disease [sixty, 61]. The same pattern has been demonstrated with lactose intolerance [62]. While each of these conditions remains in the untreated state, it appears that levothyroxine absorption is meliorate when liquid levothyroxine is utilised for patient therapy [63–65]. Nephrotic syndrome is another medical condition associated with a need for an increased dose of levothyroxine, presumably due to urinary losses of thyroid hormones, accompanying the urinary losses of thyroxine-binding globulin [66].

Medications, Supplements, and Food

Medications may alter a patient's requirement for levothyroxine through a variety of mechanisms (Table1). These mechanisms include altered levothyroxine absorption, altered thyroid hormone synthesis or release (theoretically relevant for those who still have some residue thyroid function), altered transport of levothyroxine, contradistinct metabolism of levothyroxine, and contradistinct TSH secretion. A partial list of some of the implicated drugs is shown in Table1, and more complete discussion of these drugs tin can be found in several review articles [8, 51, 67–69]. In most cases, the net event is a need for an increased levothyroxine dose. A classic instance of a medication that causes an increased requirement for levothyroxine is oestrogen therapy [lxx, 71], which is associated with increased levels of thyroxine-bounden globulin. Tyrosine kinase inhibitors can take multiple effects, including causing an increased demand for levothyroxine via increasing the metabolism of levothyroxine (Fig.five) [68, 72].

Table 1

Drugs affecting levothyroxine requirement and the mechanism of altered requirement

Drug	Altered LT4 requirement	Contradistinct LT4 absorption	Altered TH synthesis or release	Altered transport	Altered metabolism	Altered TSH secretion
Oestrogen	↑			×
Androgens	↓			×
Glucocorticoids	↓			×		×
Phenobarbital	↑				×
TKI	↑↓				×
Rifampin	↑				×
Sertraline	↑				×
Amiodarone	↑↓		×		×
Iodine	↑↓		×
Lithium	↑↓		×
Dopamine, dobutamine						×
Bexarotene	↑					×
Calcium carbonate	↑	×
PPI	↑	×
Ferrous sulphate	↑	×
Cholestyramine	↑	×
Phosphate binders	↑	×

LT4 levothyroxine, PPI proton pump inhibitors, Thursday thyroid hormone, THS thyroid-stimulating hormone, TKI tyrosine kinase inhibitors

Example of how to adjust levothyroxine dose in patients receiving concomitant medications. LT4 levothyroxine, rT3 reverse triiodothyronine, T3 triiodothyronine, TSH thyroid-stimulating hormone

If levothyroxine is ingested forth with nutrient, its absorption can be dumb [fifteen, 51]. Soy-containing foods are an example of a substance that can subtract absorption (Fig.6) [73]. Calcium supplements [74, 75] and iron [76, 77] too reduce absorption and thereby increase the levothyroxine dose requirement or increase serum TSH [52, 53]. Vitamin C stands alone equally an example of a supplement that may really decrease the requirement for levothyroxine past enhancing its absorption, at least in patients with gastritis [78].

Instance of how to adjust levothyroxine dose in patients consuming foods that may impair absorption. LT4 levothyroxine, TSH thyroid-stimulating hormone

Controversies Near Treatment Other Than Levothyroxine

No consistently stiff evidence has been found for the superiority of any alternative training (e.g., levothyroxine/liothyronine combination therapy, thyroid extract therapy, or others) over monotherapy with levothyroxine in improving health outcomes [8]. Trials of such therapy testify mixed results regarding patient preference for combination therapy or other alternative therapies [viii]. On an anecdotal basis some patients may perceive benefit from combination therapy, whereas others may non (Fig.7). However, in some patients, levothyroxine replacement is associated with significant impairment in psychological well-being [79], including compared with euthyroid controls [fourscore], and as such there is interest in studies comparing combined levothyroxine/liothyronine with levothyroxine monotherapy. One instance of a written report addressing this controversy is a randomised, double-blind written report that was carried out comparing treatment with levothyroxine/liothyronine at a ratio of five:1 or 10:1 with levothyroxine monotherapy in 141 patients (18–seventy years sometime) with principal autoimmune hypothyroidism [81]. Information technology was observed that more patients on combination therapy displayed elevated triiodothyronine levels. While patients showed a preference for the combined handling over levothyroxine therapy (the chief study upshot), the positive changes in mood, well-being, fatigue, and neurocognitive functions reported (secondary outcomes) occurred in all treatment groups and could not entirely account for the fact that the primary outcome strongly supported combined therapy. Meanwhile, a reduction in body weight, though not in serum TSH, correlated with greater satisfaction with the study medication [81]. Finally, among those patients who preferred the combined levothyroxine/liothyronine therapy, 44% had serum TSH levels < 0.11 mU/fifty.

Illustration of potential responses of a patient to a trial of combination therapy with levothyroxine and liothyronine. FT4 complimentary thyroxine, LT3 liothyronine, LT4 levothyroxine, TSH thyroid-stimulating hormone, T3 triiodothyronine

It has been hypothesised that the Thr92Ala D2 polymorphism may influence the enzymatic action of deiodinase II (DIO2), thereby predicting a positive response to combined levothyroxine/liothyronine therapy. In a study with 12,625 participants from the LifeLines cohort report using bachelor genome-broad genetic data, the effects of the Thr92Ala polymorphism (rs225014) were evaluated in the general population and in 364 individuals undergoing levothyroxine replacement therapy mainly due to principal hypothyroidism [82]. In both groups, the D2-Thr92Ala polymorphism was non associated with differences in TSH, gratuitous thyroxine and gratis triiodothyronine, presence of metabolic syndrome, other comorbidities, HRQoL, and cognitive functioning [82]. Nevertheless, new findings in rodents indicate that carriers of the Thr92Ala-D2 polymorphism may exhibit lower D2 catalytic activity and macerated thyroid hormone signalling resulting in localised/systemic hypothyroidism [83]. These findings, if replicated in humans, may widen the opportunity for a more personalised arroyo to the treatment of hypothyroidism [84].

A contempo survey, which queried the handling of hypothyroidism by presenting 13 theoretical patients and offering half dozen therapeutic options, was emailed to the members of the American Thyroid Association (ATA) prior to a satellite symposium of their Leap Coming together and also before the annual Endocrine Society and ATA Meetings. A multivariate analysis of the results revealed that doctor characteristics may touch prescription patterns, with residents of North America, for case, existence more inclined to prescribe therapies incorporating liothyronine than their colleagues in Europe [85, 86]. However, the written report was non designed to investigate whether this was due to doc-patient interaction, specific education post-obit the meetings, the influence of pharmaceutical companies, or media exposure, or a combination of these. The fact that physicians indicate their willingness to prescribe a liothyronine-containing handling may indicate a need for more inquiry to understand patient preferences, which may sway physicians' choices when considering prescribing liothyronine combined with levothyroxine, and the risks and benefits of such therapy.

Determination

This review highlights the complexity of maintaining biochemical and clinical euthyroidism in patients undergoing treatment with levothyroxine. Challenges include the physiological changes that occur as adult patients progress through the stages of life as well as the alterations in levothyroxine needs that may exist associated with concomitant medical weather condition and medications. Optimal treatment of hypothyroidism requires a partnership betwixt patient and physician. The physician is tasked with vigilant appraisement of the patient's status based on a thorough clinical and laboratory assessment and advisable adjustment of their levothyroxine therapy. The patient in plough is tasked with medication adherence and reporting of symptomatology and any changes in their medical situation. The goal is consistent maintenance of euthyroidism, without the patient experiencing the adverse events and negative wellness consequences of nether- or overtreatment.

Acknowledgements

This supplement has been sponsored by Merck.

Funding

Sponsorship for this manuscript, the Rapid Service Fees, and the Open Admission fee were all funded by Merck.

Medical Writing, Editorial, and Other Assistance

We would like to thank Simone Tait of Springer Healthcare who edited this manuscript earlier submission. This medical writing aid was funded by Merck.

Authorship

All named authors see the International Committee of Medical Periodical Editors (ICMJE) criteria for authorship for this article, have responsibleness for the integrity of the work every bit a whole, and have given their approval for this version to exist published.

Disclosures

Leonidas H. Duntas and Jacqueline Jonklaas accept nothing to disembalm related to this work. This research did not receive whatsoever specific grant from any funding agency in the public, commercial, or not-for profit sector.

Compliance with Ethics Guidelines

This commodity is based on previously conducted studies and does not contain whatever studies with animals performed by whatsoever of the authors. Some of studies cited include analyses, or studies with man participants, performed by the authors and completed prior to the initiation of this manuscript.

Footnotes

Enhanced Digital Features

To view enhanced digital features for this article go to 10.6084/m9.figshare.9706403.

References

i. Kendall EC. The isolation in crystalline class of the compound containing iodin, which occurs in the thyroid: its chemical nature and physiologic activeness. JAMA. 1915;LXIV(25):2042–2043. [PubMed] [Google Scholar]

2. Harington CR, Barger Chiliad. Chemistry of thyroxine: constitution and synthesis of thyroxine. Biochem J. 1927;21(1):169–183. [PMC gratis article] [PubMed] [Google Scholar]

3. Chalmers J, Dickson G, Elks J, Hems BA. The synthesis of thyroxine and related substances. Part V. A synthesis of l-thyroxine from l-tyrosine. J Chem Soc. 1927 [Google Scholar]

4. Slater S. The discovery of thyroid replacement therapy. Office 2: the critical 19th century. J R Soc Med. 2011;104(2):59–63. [PMC free article] [PubMed] [Google Scholar]

v. Slater S. The discovery of thyroid replacement therapy. Part i: in the outset. J R Soc Med. 2011;104(1):15–18. [PMC free article] [PubMed] [Google Scholar]

6. Bianco Air-conditioning, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38–89. [PubMed] [Google Scholar]

8. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared past the American Thyroid Clan task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751. [PMC free article] [PubMed] [Google Scholar]

9. Kabadi UM, Kabadi MM. Serum thyrotropin in principal hypothyroidism: a reliable and accurate predictor of optimal daily levothyroxine dose. Endocr Pract. 2001;seven(1):16–xviii. [PubMed] [Google Scholar]

10. Elfenbein DM, Schaefer S, Shumway C, Chen H, Sippel RS, Schneider DF. Prospective intervention of a novel levothyroxine dosing protocol based on trunk mass index after thyroidectomy. J Am Coll Surg. 2016;222(1):83–88. [PMC costless article] [PubMed] [Google Scholar]

11. Ojomo KA, Schneider DF, Reiher AE, et al. Using body mass alphabetize to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg. 2013;216(3):454–460. [PMC costless commodity] [PubMed] [Google Scholar]

12. Jin J, Allemang MT, McHenry CR. Levothyroxine replacement dosage decision later on thyroidectomy. Am J Surg. 2013;205(three):360–363. [PubMed] [Google Scholar]

13. Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the handling of thyroid diseases. J Clin Endocrinol Metab. 2005;90(ane):124–127. [PubMed] [Google Scholar]

fifteen. Bach-Huynh TG, Nayak B, Loh J, Soldin South, Jonklaas J. Timing of levothyroxine assistants affects serum thyrotropin concentration. J Clin Endocrinol Metab. 2009;94(10):3905–3912. [PMC gratuitous article] [PubMed] [Google Scholar]

16. Pecina J, Garrison GM, Bernard ME. Levothyroxine dosage is associated with stability of thyroid-stimulating hormone values. Am J Med. 2014;127(iii):240–245. [PubMed] [Google Scholar]

17. Ashrafpour R, Ayati N, Sadeghi R, et al. Comparison of treatment response accomplished by tablet splitting versus whole tablet assistants of levothyroxine in patients with thyroid cancer. Asia Ocean J Nucl Med Biol. 2018;6(2):108–112. [PMC free article] [PubMed] [Google Scholar]

18. Hepp Z, Lage MJ, Espaillat R, Gossain VV. The clan between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US. J Med Econ. 2018;21(nine):912–919. [PubMed] [Google Scholar]

19. Walker JN, Shillo P, Ibbotson V, et al. A thyroxine absorption test followed by weekly thyroxine administration: a method to appraise non-adherence to treatment. Eur J Endocrinol. 2013;168(6):913–917. [PubMed] [Google Scholar]

20. Grebe SK, Cooke RR, Ford HC, et al. Treatment of hypothyroidism with once weekly thyroxine. J Clin Endocrinol Metab. 1997;82(3):870–875. [PubMed] [Google Scholar]

21. Jauk B, Mikosch P, Gallowitsch HJ, et al. Unusual malabsorption of levothyroxine. Thyroid. 2000;10(1):93–95. [PubMed] [Google Scholar]

22. Groener JB, Lehnhoff D, Piel D, Nawroth PP, Schanz J, Rudofsky Chiliad. Subcutaneous application of levothyroxine as successful treatment pick in a patient with malabsorption. Am J Case Rep. 2013;14:48–51. [PMC complimentary article] [PubMed] [Google Scholar]

23. Taylor PN, Tabasum A, Sanki G, et al. Weekly intramuscular injection of levothyroxine post-obit myxoedema: a practical solution to an old crisis. Case Rep Endocrinol. 2015;2015:169194. [PMC free article] [PubMed] [Google Scholar]

24. Ernst FR, Barr P, Elmor R, et al. The economic impact of levothyroxine dose adjustments: the CONTROL HE study. Clin Drug Investig. 2017;37(i):71–83. [PMC costless commodity] [PubMed] [Google Scholar]

25. Livadas South, Bothou C, Androulakis I, Boniakos A, Angelopoulos N, Duntas 50. Levothyroxine replacement therapy and overuse: a timely diagnostic approach. Thyroid. 2018;28:1580–1586. [Google Scholar]

26. Younis IR, Ahmed MA, Burman KD, Soldin OP, Jonklaas J. Stable isotope pharmacokinetic studies provide insight into effects of age, sex, and weight on levothyroxine metabolism. Thyroid. 2018;28(ane):41–49. [PMC free article] [PubMed] [Google Scholar]

27. Shrestha RT, Malabanan A, Haugen BR, Levy EG, Hennessey JV. Agin consequence reporting in patients treated with thyroid hormone excerpt. Endocr Pract. 2017;23(5):566–575. [PubMed] [Google Scholar]

28. Balsa AM, Ferreira AR, Alves M, Guimarães J. Takotsubo cardiomyopathy associated with levothyroxine over-replacement. Eur Endocrinol. 2017;13(1):30–32. [PMC free article] [PubMed] [Google Scholar]

29. Kim MK, Yun KJ, Kim MH, et al. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone. 2015;71:101–105. [PubMed] [Google Scholar]

thirty. Vigário Pdos S, Vaisman F, Coeli CM, et al. Inadequate levothyroxine replacement for master hypothyroidism is associated with poor wellness-related quality of life-a Brazilian multicentre report. Endocrine. 2013;44(ii):434–440. [PubMed] [Google Scholar]

32. Blakesley Five, Awni W, Locke C, Ludden T, Granneman GR, Braverman LE. Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid. 2004;fourteen(iii):191–200. [PubMed] [Google Scholar]

33. Wartofsky L. Levothyroxine: therapeutic apply and regulatory problems related to bioequivalence. Good Opin Pharmacother. 2002;three(six):727–732. [PubMed] [Google Scholar]

34. Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the american thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315–389. [PubMed] [Google Scholar]

35. Loh JA, Wartofsky L, Jonklaas J, Burman KD. The magnitude of increased levothyroxine requirements in hypothyroid pregnant women depends upon the etiology of the hypothyroidism. Thyroid. 2009;nineteen(iii):269–275. [PubMed] [Google Scholar]

36. Abalovich One thousand, Alcaraz G, Kleiman-Rubinsztein J, et al. The relationship of preconception thyrotropin levels to requirements for increasing the levothyroxine dose during pregnancy in women with primary hypothyroidism. Thyroid. 2010;20(ten):1175–1178. [PubMed] [Google Scholar]

37. Yassa L, Marqusee East, Fawcett R, Alexander EK. Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. J Clin Endocrinol Metab. 2010;95(7):3234–3241. [PubMed] [Google Scholar]

38. Sullivan SD, Downs East, Popoveniuc G, Zeymo A, Jonklaas J, Burman KD. Randomized trial comparison two algorithms for levothyroxine dose adjustment in significant women with chief hypothyroidism. J Clin Endocrinol Metab. 2017;102(9):3499–3507. [PubMed] [Google Scholar]

39. Busnelli A, Vannucchi G, Paffoni A, et al. Levothyroxine dose adjustment in hypothyroid women achieving pregnancy through IVF. Eur J Endocrinol. 2015;173(iv):417–424. [PubMed] [Google Scholar]

twoscore. Devdhar M, Drooger R, Pehlivanova M, Singh G, Jonklaas J. Levothyroxine replacement doses are affected by gender and weight, but not historic period. Thyroid. 2011;21(8):821–827. [PMC free article] [PubMed] [Google Scholar]

41. Michalaki MA, Gkotsina MI, Mamali I, et al. Impaired pharmacokinetics of levothyroxine in severely obese volunteers. Thyroid. 2011;21(5):477–481. [PubMed] [Google Scholar]

42. Gadiraju S, Lee CJ, Cooper DS. Levothyroxine dosing following bariatric surgery. Obes Surg. 2016;26(10):2538–2542. [PubMed] [Google Scholar]

43. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. [PubMed] [Google Scholar]

44. Fallahi P, Ferrari SM, Camastra Southward, et al. TSH normalization in bariatric surgery patients after the switch from l-thyroxine in tablet to an oral liquid conception. Obes Surg. 2017;27(1):78–82. [PubMed] [Google Scholar]

45. Jonklaas J. Sex activity and historic period differences in levothyroxine dosage requirement. Endocr Pract. 2010;16(1):71–79. [PubMed] [Google Scholar]

46. Baehr KM, Lyden E, Treude K, Erickson J, Goldner Westward. Levothyroxine dose following thyroidectomy is affected by more than than merely torso weight. Laryngoscope. 2012;122(4):834–838. [PubMed] [Google Scholar]

47. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):769–780. [PubMed] [Google Scholar]

48. Sawin CT, Herman T, Molitch ME, London MH, Kramer SM. Crumbling and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med. 1983;75(2):206–209. [PubMed] [Google Scholar]

49. Del Duca SC, Santaguida MG, Brusca N, et al. Individually-tailored thyroxine requirement in the same patients before and after thyroidectomy: a longitudinal study. Eur J Endocrinol. 2015;173(3):351–357. [PubMed] [Google Scholar]

50. Boucai L, Hollowell JG, Surks MI. An arroyo for evolution of age-, gender-, and ethnicity-specific thyrotropin reference limits. Thyroid. 2011;21(1):five–11. [PMC free article] [PubMed] [Google Scholar]

51. Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni Thousand. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019;40(i):118–136. [PubMed] [Google Scholar]

52. McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, concomitant medications, and diet equally factors affecting levothyroxine therapy: results of the Command surveillance projection. Drugs R D. 2016;16(1):53–68. [PMC free article] [PubMed] [Google Scholar]

53. Robertson HM, Narayanaswamy AK, Pereira O, et al. Factors contributing to loftier levothyroxine doses in master hypothyroidism: an interventional audit of a large community database. Thyroid. 2014;24(12):1765–1771. [PubMed] [Google Scholar]

54. Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry Assay 1987–2012. J Clin Endocrinol Metab. 2015;100(ix):3270–3279. [PMC free article] [PubMed] [Google Scholar]

55. Imberti R, Ferrari M, Albertini R, Rizzo V, Tinelli C, Iotti GA. Increased levothyroxine requirements in critically ill patients with hypothyroidism. Minerva Anestesiol. 2010;76(vii):500–503. [PubMed] [Google Scholar]

56. Pirola I, Daffini L, Gandossi E, et al. Comparison betwixt liquid and tablet levothyroxine formulations in patients treated through enteral feeding tube. J Endocrinol Investig. 2014;37(vi):583–587. [PubMed] [Google Scholar]

57. Barrett NA, Jones A, Whiteley C, Yassin Due south, McKenzie CA. Management of long-term hypothyroidism: a potential mark of quality of medicines reconciliation in the intensive care unit. Int J Pharm Pract. 2012;20(5):303–306. [PubMed] [Google Scholar]

58. Centanni M, Gargano L, Canettieri Grand, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. Due north Engl J Med. 2006;354(17):1787–1795. [PubMed] [Google Scholar]

59. Bugdaci MS, Zuhur SS, Sokmen M, Toksoy B, Bayraktar B, Altuntas Y. The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine. Helicobacter. 2011;16(2):124–130. [PubMed] [Google Scholar]

60. Collins D, Wilcox R, Nathan Thou, Zubarik R. Celiac disease and hypothyroidism. Am J Med. 2012;125(iii):278–282. [PubMed] [Google Scholar]

61. Virili C, Bassotti Thou, Santaguida MG, et al. Atypical celiac illness equally cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab. 2012;97(3):E419–E422. [PubMed] [Google Scholar]

62. Cellini M, Santaguida MG, Gatto I, et al. Systematic appraisal of lactose intolerance as cause of increased need for oral thyroxine. J Clin Endocrinol Metab. 2014;99(8):E1454–E1458. [PubMed] [Google Scholar]

63. Ribichini D, Fiorini G, Repaci A, et al. Tablet and oral liquid l-thyroxine conception in the treatment of naive hypothyroid patients with Helicobacter pylori infection. Endocrine. 2017;57(3):394–401. [PubMed] [Google Scholar]

64. Fallahi P, Ferrari SM, Marchi Southward, De Bortoli Northward, Ruffilli I, Antonelli A. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine. 2017;57(i):175–178. [PubMed] [Google Scholar]

65. Santaguida MG, Virili C, Del Duca SC, et al. Thyroxine softgel sheathing in patients with gastric-related T4 malabsorption. Endocrine. 2015;49(1):51–57. [PubMed] [Google Scholar]

66. Karethimmaiah H, Sarathi 5. Nephrotic syndrome increases the need for levothyroxine replacement in patients with hypothyroidism. J Clin Diagn Res. 2016;ten(12):OC10–OC12. [PMC free commodity] [PubMed] [Google Scholar]

67. Liwanpo Fifty, Hershman JM. Weather and drugs interfering with thyroxine absorption. All-time Pract Res Clin Endocrinol Metab. 2009;23(6):781–792. [PubMed] [Google Scholar]

68. Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side outcome of anticancer drugs. Thyroid. 2013;23(11):1345–1366. [PubMed] [Google Scholar]

69. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med. 1995;333(25):1688–1694. [PubMed] [Google Scholar]

70. Irving SA, Vadiveloo T, Leese GP. Drugs that collaborate with levothyroxine: an observational study from the Thyroid Epidemiology, Audit and Inquiry Study (TEARS) Clin Endocrinol (Oxf) 2015;82(1):136–141. [PubMed] [Google Scholar]

71. Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. Due north Engl J Med. 2001;344(23):1743–1749. [PubMed] [Google Scholar]

72. Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type iii deiodination. J Clin Endocrinol Metab. 2010;95(8):3758–3762. [PubMed] [Google Scholar]

73. Messina One thousand, Redmond Yard. Effects of soy protein and soybean isoflavones on thyroid role in salubrious adults and hypothyroid patients: a review of the relevant literature. Thyroid. 2006;sixteen(3):249–258. [PubMed] [Google Scholar]

74. Singh N, Weisler SL, Hershman JM. The acute consequence of calcium carbonate on the abdominal assimilation of levothyroxine. Thyroid. 2001;eleven(10):967–971. [PubMed] [Google Scholar]

75. Zamfirescu I, Carlson HE. Assimilation of levothyroxine when coadministered with various calcium formulations. Thyroid. 2011;21(5):483–486. [PMC complimentary article] [PubMed] [Google Scholar]

76. Shakir KM, Chute JP, Aprill BS, Lazarus AA. Ferrous sulfate-induced increment in requirement for thyroxine in a patient with primary hypothyroidism. Due south Med J. 1997;90(half dozen):637–639. [PubMed] [Google Scholar]

77. Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med. 1992;117(12):1010–1013. [PubMed] [Google Scholar]

78. Jubiz Westward, Ramirez M. Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis. J Clin Endocrinol Metab. 2014;99(6):E1031–E1034. [PubMed] [Google Scholar]

79. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707–721. [PMC gratuitous article] [PubMed] [Google Scholar]

fourscore. Saravanan P, Chau WF, Roberts Northward, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002;57(5):577–585. [PubMed] [Google Scholar]

81. Appelhof BC, Fliers Eastward, Wekking EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in chief hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab. 2005;xc(5):2666–2674. [PubMed] [Google Scholar]

82. Wouters HJ, van Loon HC, van der Klauw MM, et al. No effect of the Thr92Ala polymorphism of deiodinase-two on thyroid hormone parameters, wellness-related quality of life, and cognitive performance in a large population-based cohort report. Thyroid. 2017;27(2):147–155. [PubMed] [Google Scholar]

83. Jo S, Fonseca TL, Bocco B, et al. Type 2 deiodinase polymorphism causes ER stress and hypothyroidism in the encephalon. J Clin Investig. 2019;129(1):230–245. [PMC free article] [PubMed] [Google Scholar]

84. Bianco Air conditioning, Kim BS. Pathophysiological relevance of deiodinase polymorphism. Curr Opin Endocrinol Diabetes Obes. 2018;25(5):341–346. [PMC free article] [PubMed] [Google Scholar]

85. Jonklaas J, Tefera Due east, Shara Northward. Short-term time trends in prescribing therapy for hypothyroidism: results of a survey of American Thyroid Association members. Front Endocrinol (Lausanne). 2019;10:31. [PMC free article] [PubMed] [Google Scholar]

86. Jonklaas J, Tefera E, Shara Northward. Prescribing therapy for hypothyroidism: influence of physician characteristics. Thyroid. 2019;29(1):44–52. [PMC gratis article] [PubMed] [Google Scholar]

cardenasevied1952.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822824/

Share this post